Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Nakano Kazuhiko, Ohta Shigeyuki, Komatsu Kenji, Kubo Taro, Nukui Akinori, Suzuki Kazumi, Kurokawa Shinsuke, Kobayashi Minoru, Morita Tatsuo
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2012-02-01
Ráidu:	BMC Urology
Liŋkkat:	http://www.biomedcentral.com/1471-2490/12/3
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!